切换至 "中华医学电子期刊资源库"

中华诊断学电子杂志 ›› 2018, Vol. 06 ›› Issue (02) : 134 -138. doi: 10.3877/cma.j.issn.2095-655X.2018.02.017

所属专题: 文献

临床研究

Vimentin和Ki-67在肾癌中的表达及其临床意义
刘德乾1, 赵战魁2,(), 孟琳2, 张雪1, 陈晔2   
  1. 1. 272067 济宁医学院
    2. 272029 济宁医学院附属医院泌尿外科
  • 收稿日期:2017-10-23 出版日期:2018-05-26
  • 通信作者: 赵战魁
  • 基金资助:
    国家自然科学基金(8150041576)

Clinical significance of Vimentin and Ki-67 expression in renal cell carcinoma

Deqian Liu1, Zhankui Zhao2,(), Lin Meng2, Xue Zhang1, Ye Chen2   

  1. 1. Jining Medical University, Jining, 272067
    2. Department of Urology, the Affiliated Hospital of Jining Medical University, Jinning, 272029, China
  • Received:2017-10-23 Published:2018-05-26
  • Corresponding author: Zhankui Zhao
  • About author:
    Corresponding author: Zhao Zhankui, Email:
引用本文:

刘德乾, 赵战魁, 孟琳, 张雪, 陈晔. Vimentin和Ki-67在肾癌中的表达及其临床意义[J/OL]. 中华诊断学电子杂志, 2018, 06(02): 134-138.

Deqian Liu, Zhankui Zhao, Lin Meng, Xue Zhang, Ye Chen. Clinical significance of Vimentin and Ki-67 expression in renal cell carcinoma[J/OL]. Chinese Journal of Diagnostics(Electronic Edition), 2018, 06(02): 134-138.

目的

观察Vimentin和Ki-67在肾癌(RCC)组织中的表达,探讨Vimentin和Ki-67在RCC发生、发展中的作用及其相互关系。

方法

收集2016年1月至2017年6月在济宁医学院附属医院泌尿外科行手术治疗的133例RCC患者的临床资料。应用免疫组化方法(SP法)检测不同组织中Vimentin和Ki-67的表达情况,并与肿瘤临床分期、组织学分级及肿瘤大小进行相关性分析。

结果

Vimentin及Ki-67在RCC组织中均异常高表达,在癌旁正常肾组织中均不表达,差异具有统计学意义(χ2=58.86,P<0.05;χ2=26.67,P<0.05);Vimentin和Ki-67的表达在不同RCC患者性别(χ2=4.07,1.16;P>0.05)、年龄(χ2=0.03,0.87;P>0.05)、肿瘤位置(χ2=0.00,0.00;P>0.05)之间的差异无统计学意义,在RCC的临床分期(χ2=10.66,P<0.01;χ2=19.88,P<0.01)、组织学分级(χ2=13.79,P<0.01;χ2=21.03,P<0.01)、肿瘤的大小(χ2=19.52,P<0.01;χ2=16.10,P<0.01)差异具有统计学意义,两者的表达呈正相关(r=0.46,P<0.05)。

结论

Vimentin和Ki-67参与了RCC的发生发展,其表达水平与组织学分级、临床分期、肿瘤大小有关,组织学分级越高、临床分期越晚、肿瘤体积越大,两者的表达水平越高,两者在肿瘤的进展中可能起到协同作用。

Objective

To observe the expression levels of Vimentin and Ki-67 in the occurrence and development of renal cell carcinoma (RCC) and explore the possible correlation between the expression of Vimentin/Ki-67 and clinical significance.

Methods

The clinical data of 133 patients who underwent surgical operation from January 2016 to June 2017 were reviewed. SP immunohistochemical staining was used to explore the expression levels of Vimentin and Ki-67 in different tissues. Correlation analysis was carried out between the expression results and the clinical stage, histological grade and tumor size.

Results

Both Vimentin and Ki-67 showed positive expression in renal cell carcinoma, but no expression was found in the adjacent normal renal tissue. Vimentin was mainly expressed in the cytoplasm of the cells while Ki-67 expressed in nucleus. There was significant difference between renal cell carcinoma and adjacent normal renal tissue (χ2=58.86, P<0.05; χ2=26.67, P<0.05). There were no significant differences between Vimentin/Ki-67 expression levels in different gender (χ2=4.07, P>0.05; χ2=1.16, P>0.05), age(χ2=0.03, P>0.05; χ2=0.87, P>0.05) and location(χ2=0.00, P>0.05; χ2=0.00, P>0.05)of renal cell carcinoma patients. However, there were significant differences between different clinical stage (χ2=10.66, P<0.01; χ2=19.88, P<0.01), histological grade (χ2=13.79, P<0.01; χ2=21.03, P<0.01) and tumor size (χ2=19.52, P<0.01; χ2=16.10, P<0.01). There was positive correlation between Vimentin/Ki-67 (r=0.46, P<0.05).

Conclusions

Vimentin and Ki-67 are involved in the development of renal cell carcinoma, and their expression levels are related to the clinical stage, histological grade and tumor size. High expression levels of Vimentin and Ki-67 are presented in carcinoma tissues with high clinical stage, late histological grade and big tumor. Both of them may play a synergistic role in the progression of the carcinoma.

表1 Vimentin和Ki-67在肾癌组织和癌旁正常肾组织中的表达情况比较(例数)
图1 Vimentin和Ki-67在肾癌组织中的表达情况
表2 Vimentin和Ki-67在不同年龄、性别、位置、肿瘤大小的表达情况比较(例数)
表3 Vimentin和Ki-67与肾癌组织学分级、临床分期的关系(例数)
表4 Vimentin和Ki-67在肾癌组织中表达的相关性分析
[1]
辛军,周金,欧阳永娥,等.Survivin和Ki-67在肾癌中的表达及其临床意义[J].现代泌尿生殖肿瘤杂志,2014,6(2):98-101.
[2]
Hari DM,Leung AM,Lee JH,et al.AJCC Cancer Staging Manual 7th edition criteria for colon cancer: do the complex modifications improve prognostic assessment?[J].J Am Coll Surg,2013,217(2):181-190.
[3]
孙燕,王凡.Vimentin在肾透明细胞癌中的表达及临床意义[J].现代肿瘤医学,2015,23(20):2990-2993.
[4]
谢金玲,卓少元.Vimentin在原发性肝癌发生发展及凋亡过程中的作用[J].中国肿瘤,2017,26(2):130-134.
[5]
Ivaska J, Pallari HM, Nevo J, et al.Novel functions of vimentin in cell adhesion, migration, and signaling[J].Exp Cell Res, 2007,313(10):2050-2062.
[6]
Gawlitta W,Osborn M,Weber K.Coiling of intermediate filaments induced by microinjection of a vimentin-specific antibody does not interfere with locomotion and mitosis[J].Eur J Cell Biol, 1981,26(1):83-90.
[7]
Lindsay CR, Le Moulec S, Billiot F, et al.Vimentin and Ki67 expression in circulating tumour cells derived from castrate-resistant prostate cancer[J].BMC Cancer, 2016(16):168.
[8]
Holthöfer H, Miettinen A, Paasivuo R, et al.Cellular origin and differentiation of renal carcinomas.A fluorescence microscopic study with kidney-specific antibodies, antiintermediate filament antibodies, and lectins[J].Lab Invest, 1983,49(3):317-326.
[9]
Polioudaki H, Agelaki S, Chiotaki R, et al.Variable expression levels of keratin and vimentin reveal differential EMT status of circulating tumor cells and correlation with clinical characteristics and outcome of patients with metastatic breast cancer[J].BMC Cancer, 2015(15):399.
[10]
万安,周颖,曲皖君,等.子宫颈癌中vimentin和ki-67蛋白表达及其影响因素分析[J].中华疾病控制杂志,2014,18(9):805-807.
[11]
Lawrence NF, Hammond MR, Frederick DT, et al.Ki-67, p53,and p16 expression,and G691S RET polymorphism in desmoplastic melanoma (DM): a clinicopathologic analysis of predictors of outcome[J].J Am Acad Dermatol, 2016,75(3):595-602.
[12]
Gerdes J, Lemke H, Baisch H, et al.Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67[J].J Immunol,1984,133(4):1710-1715.
[13]
吕旭,姜叶娟,王香,等.p53与Ki-67在胃癌组织中表达与淋巴转移的关系[J].中华疾病控制杂志,2015,19(4):407-410.
[14]
娄雪玲,周梅玲,张占薪,等.雌激素受体、孕激素受体、C-erbB-2和Ki-67在子宫内膜癌中的表达及其与临床病理相关性[J].中国实用妇科与产科杂志,2014(7):557-560.
[15]
郭云娣,张雅琴,白光辉.APE1和Ki67蛋白在胃癌组织中的表达及其临床意义[J].江苏医药,2012(19):2290-2292.
[16]
Nakajima M,Sawada H,Yamada Y,et al.The prognostic significance of amplification and overexpression of c-met and c-erb B-2 in human gastric carcinomas[J].Cancer, 1999,85(9):1894-1902.
[17]
Bouzubar N, Walker KJ, Griffiths K, et al.Ki67 immunostaining in primary breast cancer: pathological and clinical associations[J].Br J Cancer, 1989,59(6):943-947.
[18]
Carreras R, Alameda F, Mancebo G, et al.A study of Ki-67,c-erbB2 and cyclin D-1 expression in CIN-Ⅰ,CIN-Ⅲ and squamous cell carcinoma of the cervix[J].Histol Histopathol, 2007,22(6):587-592.
[19]
杨映红,林明稀,郑宇辉,等.分化抑制蛋白Id1和PCNA及Ki67在肝细胞癌中的表达及意义[J].中国肿瘤临床与康复,2008,15(1):30-32.
[1] 张妍, 原韶玲, 史泽洪, 郭馨阳, 牛菁华. 小肾肿瘤超声漏诊原因分析新思路[J/OL]. 中华医学超声杂志(电子版), 2024, 21(05): 500-504.
[2] 赵阳, 肖迎聪, 巨艳, 党晓智, 蔡林利, 薛文欣, 李洋, 肖瑶, 郭妤绮, 宋宏萍. 自动乳腺超声联合免疫组化早期预测乳腺癌新辅助化疗病理完全缓解的临床价值[J/OL]. 中华医学超声杂志(电子版), 2024, 21(04): 361-369.
[3] 武壮壮, 张晓娟, 史泽洪, 史瑶, 原韶玲. 超声联合乳腺X线摄影及PR、Her-2预测高级别与中低级别乳腺导管原位癌的价值[J/OL]. 中华医学超声杂志(电子版), 2023, 20(06): 631-635.
[4] 贺媛媛, 李佳, 杨红. 宫颈中肾腺癌1例并文献复习[J/OL]. 中华妇幼临床医学杂志(电子版), 2024, 20(01): 97-104.
[5] 陈怡芳, 黄晓卉. 肝细胞癌中对氧磷酶2的表达及临床意义[J/OL]. 中华普通外科学文献(电子版), 2024, 18(03): 186-191.
[6] 刘政宏, 王凤力, 吉亚君, 高佳. 胃癌中ELK3蛋白的表达与临床病理特征和预后的关系研究[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(02): 155-159.
[7] 冯冰, 邹秋果, 梁振波, 卢艳明, 曾奕, 吴淑苗. 老年非特殊型浸润性乳腺癌超声征象与分子生物学指标的临床研究[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(01): 48-51.
[8] 谢汶歆, 马乐, 刘晔, 曹晓明, 张万春. 前列腺特异性膜抗原PET/CT在肾癌诊疗中的应用价值[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2024, 18(05): 514-519.
[9] 张超, 过菲, 王富博, 叶宸, 杨悦, 杨波. 腹腔镜肾部分切除术:肾癌合并肾静脉癌栓的新选择[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2024, 18(03): 219-224.
[10] 张子旭, 郑俊炯, 罗云, 林天歆. 腹腔镜肾部分切除术离体猪肾培训模型的构建[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2024, 18(03): 277-283.
[11] 邓永豪, 曹嘉正. 长链非编码RNA与肾癌的关系及其在肾癌中的临床应用[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2024, 18(03): 289-293.
[12] 赵佳晖, 王永兴, 彭涛, 李明川, 魏德超, 韩毅力, 侯铸, 姜永光, 罗勇. 后腹腔镜根治性肾切除手术时间延长和术中出血量增多的影响因素分析[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2023, 17(06): 575-580.
[13] 李静波, 朱嘉宁, 宋禄达, 罗渝昆, 李秋洋. 多模态超声成像技术在肾肿瘤诊断中的应用进展[J/OL]. 中华肾病研究电子杂志, 2023, 12(06): 349-353.
[14] 谭瑞义. 小细胞骨肉瘤诊断及治疗研究现状与进展[J/OL]. 中华临床医师杂志(电子版), 2024, 18(08): 781-784.
[15] 岳瑞雪, 孔令欣, 郝鑫, 杨进强, 韩猛, 崔国忠, 王建军, 张志生, 孔凡庭, 张维, 何文博, 李现桥, 周新平, 徐东宏, 胡崇珠. 乳腺癌HER2蛋白表达水平预测新辅助治疗疗效的真实世界研究[J/OL]. 中华临床医师杂志(电子版), 2023, 17(07): 765-770.
阅读次数
全文


摘要